Replies to post #155346 on Amarin Corp Plc (AMRN)

[IgnoranceIsBliss]

While Vascepa may very well have benefits beyond CV, it would likely take a very large, expensive, and long trial to prove it.

Interesting that you say that, because they just completed a very large, expensive, and long trial that has Total Mortality as a secondary endpoint.

Hopefully all the prior SEs are stat sig so we can have that data point available for label consideration.